Ductal carcinoma in situ: a challenging disease
نویسندگان
چکیده
منابع مشابه
Ductal carcinoma in situ.
Management of ductal carcinoma in situ (DCIS) has evolved from radical surgery to the option of a more minimally invasive approach. Data show that breast conservation surgery performed with administration of radiotherapy, like mastectomy, is feasible and safe. Because efforts to find a safe group for elimination of radiotherapy have resulted in data that conflict, radiotherapy still remains sta...
متن کاملBreast Ductal Carcinoma In Situ
Ductal carcinoma in situ (DCIS) of the breast is becoming one of the most important diseases diagnosed in preventive medicine screening. The current age-adjusted incidence rate of DCIS is 32.5 per 100,000 women. For women 50–64 years of age, the incidence is approximately 88 per 100,000. Currently, for every 4 diagnoses of invasive breast cancer, there is 1 diagnosis of DCIS. Risk of DCIS is ra...
متن کاملChallenging paradigms: long non-coding RNAs in breast ductal carcinoma in situ (DCIS)
OVERVIEW The continuing challenges to the treatment of breast ductal carcinoma in situ (DCIS) warrant a new avenue of investigation. In parallel, a startling revelation of the first post-genomic decade has been the rising prominence of long non-coding RNAs (lncRNAs) as key gene regulators, including in breast cancer. High-throughput experimental surveys of the human transcriptome show that lncR...
متن کاملDuctal carcinoma in situ (DCIS) in Karachi.
OBJECTIVE To study the frequency of ductal carcinoma in situ (DCIS) in a large pathology series. DCIS is a proliferation of non-invasive, malignant epithelial cells within the ductolobular system of the breast. It is a heterogeneous entity with several morphologic variants that differ in gross appearance, growth pattern, cytologic features, mammography, and malignant potential. METHODS The da...
متن کاملTamoxifen Initiation After Ductal Carcinoma In Situ
BACKGROUND Endocrine therapy initiation after ductal carcinoma in situ (DCIS) is highly variable and largely unexplained. National guidelines recommend considering tamoxifen for women with estrogen receptor-positive (ER+) DCIS or who undergo excision alone. We evaluated endocrine therapy use after DCIS over a 15-year period in an integrated health care setting to identify factors related to ini...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Oncology Reviews
سال: 2011
ISSN: 1970-5565,1970-5557
DOI: 10.4081/oncol.2010.191